In addition, the efficacy of tofacitinib 10 mg/day for MDA5-DM with RP-ILD refractory to the triple therapy was suggested. However, the effect of those therapies was evaluated only in comparison to ...

In a phase II, 16-week, randomised, placebo-controlled, dose-ranging study in adult patients with ankylosing spondylitis (NCT01786668), tofacitinib 5 mg and 10 mg two times per day demonstrated ...

Tofacitinib 10 mg twice-daily has been demonstrated to slow radiographic progression, and patients treated with the 5 mg twice-daily dose demonstrated less radiographic progression compared with ...

The committee voted unanimously (15-0) in favour of the extension of the use of tofacitinib 10 mg BID from eight to 16 weeks of induction in adult patients who have not achieved adequate ...

ACR20 response rates were significantly greater in tofacitinib treatment versus placebo at 5 mg bid (RR 2.20; 95% CI 1.58, 3.07) and 10 mg bid (RR 2.38; 95% CI 1.81, 3.14) after 12 weeks of treatment.

Methods Pooled data from six phase 3 studies in patients receiving tofacitinib 5 mg (N=1589) or 10 mg (N=1611) twice daily or placebo (advancing to active treatment at months 3 or 6; N=680), ...

Treatment with tofacitinib 10 mg daily rapidly induced a clinical decrease in disease activity with corticosteroid tapering. At 12 months of treatment, she was in stable clinical remission and free ...

Systemic JAK inhibitor therapy with tofacitinib was associated with the most favorable outcomes among patients with extensive vitiligo.

In OCTAVE Induction 1 and 2, treatment-emergent AEs were reported in 56.5% (259) and 54.1% (232) of patients taking tofacitinib 10 mg BID, as compared to 59.8% (73) and 52.7% (59) of patients in ...

Two months prior to admission, he started to take tofacitinib 10 mg/day. On admission, we noted a rash with a blister on the forehead, and herpes zoster was diagnosed. Cerebrospinal fluid examination ...

All patients were female and the average age at diagnosis was 10.67 years. At initiation of ... mg qd), HCQ (100 mg bid), Cys A (morning: 50 mg, evening: 25 mg), belimumab (480 mg q4w IV). Reason for ...